Study to Understand Novel Biomarkers in Researching Dementia

Description

The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.

Conditions

Alzheimer Disease, Mild Cognitive Impairment, Dementia

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.

Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis

Study to Understand Novel Biomarkers in Researching Dementia

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * At least 60 years of age
  • * 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider
  • * All SEABIRD participants will be invited to participate regardless of their cognitive status
  • * Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment
  • * Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection
  • * Taking a disease-modifying drug for AD at time of enrollment
  • * Blood transfusion in the last three months
  • * Unwilling or unable to participate in all study activities

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Washington University School of Medicine,

Randall Bateman, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

David Carr, MD, STUDY_DIRECTOR, Washington University School of Medicine

Study Record Dates

2028-12